Autopsy report · NCT01282476

Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“slow accrual”

The sponsor’s own words in the registry.

Life of this trial

Registered 5 months before it started.
Ran for about 3 years 2 months before it stopped.
18 participants enrolled.
Results were posted on the registry 2 years 8 months after it ended.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: Massachusetts General Hospital
Sponsor type: University, hospital or other
Conditions: Diffuse Large B Cell Lymphoma
Interventions: Panobinostat with Rituximab
Participants: 18
Sites: 3
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.